D.E. Shaw & Co
AEGR

D.E. Shaw & Co’s Aegerion Pharmaceuticals AEGR Stock Holding History

D.E. Shaw & Co’s Portfolio AEGR Stock Details AEGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-31,116
Closed -$423K – 4084
2015
Q3 		$423K Sell
31,116
-54,365
-64% -$968K ﹤0.01% 3165
2015
Q2 		$1.62M Sell
85,481
-9,797
-10% -$212K ﹤0.01% 2350
2015
Q1 		$2.49M Buy
95,278
+75,855
+391% +$1.93M ﹤0.01% 1849
2014
Q4 		$407K Sell
19,423
-253,761
-93% -$6.39M ﹤0.01% 3471
2014
Q3 		$9.12M Buy
273,184
+164,317
+151% +$5.1M 0.01% 1152
2014
Q2 		$3.49M Buy
108,867
+36,079
+50% +$1.34M ﹤0.01% 1869
2014
Q1 		$3.36M Buy
72,788
+16,154
+29% +$947K ﹤0.01% 1889
2013
Q4 		$4.02M Buy
56,634
+35,241
+165% +$2.69M 0.01% 1885
2013
Q3 		$1.83M Sell
21,393
-49,735
-70% -$4.22M ﹤0.01% 2508
2013
Q2 		$4.5M Buy
+71,128
New +$3.78M 0.01% 1442

Other funds holding AEGR

ACM
Americafirst Capital Management Roseville, California $74M AUM 13.49% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

D.E. Shaw & Co's AEGR Position: Q4 2015 in Review

D.E. Shaw & Co sold out of Aegerion Pharmaceuticals (AEGR) in Q4 2015, closing a stake of 31,116 shares — an estimated $423K sold.

D.E. Shaw & Co first reported a position in AEGR in Q2 2013 and held it in 10 quarters. The position peaked at $9.12M in Q3 2014. 109 funds tracked by Wall St. Rank hold AEGR as of Q4 2015.

  • D.E. Shaw & Co reported no remaining Aegerion Pharmaceuticals position as of Q4 2015 after selling out during the quarter.
  • D.E. Shaw & Co sold 31,116 Aegerion Pharmaceuticals shares in Q4 2015, an estimated $423K.
  • D.E. Shaw & Co first reported a position in Aegerion Pharmaceuticals in Q2 2013 and held it in 10 quarters.
  • D.E. Shaw & Co's Aegerion Pharmaceuticals position peaked at $9.12M in Q3 2014.
  • 109 funds tracked by Wall St. Rank held Aegerion Pharmaceuticals as of Q4 2015.

Based on D.E. Shaw & Co's 13F filing for Q4 2015, filed 16 Feb 2016.